Journal Watch · Cancer Cell · 2026

γδ T cells modulate anti-tumor immunity in small cell lung cancer.

Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.

Ng J, You Y, Zhang TZ et al.Cancer Cell3 min readPharma relevance 85/100

DOI: 10.1016/j.ccell.2026.08.015PMID: 42759517Study type: genomics / omics study

TL;DR

Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.

Key findings

  • Indeed, high γδ T cell infiltration in two practice-changing clinical trials predicted improved response to anti-PD-L1 immunotherapy in patients with SCLC.
  • Moreover, using preclinical models, we demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate, an FDA-approved compound, can sensitize SCLC cells to γδ T cell-mediated killing.
  • Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.

What they did

Leveraging single-cell approaches, we discovered γδ T cell infiltration in biospecimens from patients with SCLC. Despite PD-1 expression, γδ T cells maintained a cytotoxic transcriptional profile, suggesting an anti-tumor role.

Full abstract (original)

Background: Small cell lung cancer (SCLC) is a highly aggressive neoplasm with limited sensitivity to anti-PD-(L)1 blockade, which is likely caused by the epigenetic silencing of MHC-I. Elucidating MHC-I-independent immune recognition mechanisms is therefore crucial for enhancing treatment responses and improving clinical outcomes in a greater number of patients.

What they did: Leveraging single-cell approaches, we discovered γδ T cell infiltration in biospecimens from patients with SCLC. Despite PD-1 expression, γδ T cells maintained a cytotoxic transcriptional profile, suggesting an anti-tumor role.

Results & conclusions: Indeed, high γδ T cell infiltration in two practice-changing clinical trials predicted improved response to anti-PD-L1 immunotherapy in patients with SCLC. Moreover, using preclinical models, we demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate, an FDA-approved compound, can sensitize SCLC cells to γδ T cell-mediated killing. Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.

Abstract © the authors / Cancer Cell (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.ccell.2026.08.015 · PubMed 42759517.

Why it matters for pharma & biotech

  • Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Cancer Cell study find?

Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.

What type of study is this?

It is a genomics / omics study, published in Cancer Cell in 2026. Leveraging single-cell approaches, we discovered γδ T cell infiltration in biospecimens from patients with SCLC.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.ccell.2026.08.015. PubMed ID: 42759517. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ng J, You Y, Zhang TZ et al.. γδ T cells modulate anti-tumor immunity in small cell lung cancer.. Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.08.015.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/t-cells-modulate-anti-tumor-immunity-in-small-cell-lung-cancer-608015/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides